Glaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting

Reuters04-06

Glaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting

Glaukos disclosed multiple clinical study readouts on its glaucoma implants and corneal cross-linking therapy slated for presentation at ASCRS Annual Meeting in Washington on April 10-13, 2026.
Scheduled talks include follow-up results for third-generation trabecular micro-bypass stents, with outcomes positioned to support durability of pressure-lowering benefit in open-angle glaucoma.
Additional presentations will cover real-world experience combining micro-bypass stents with Glaukos intracameral travoprost implant, highlighting treatment-effect persistence and use alongside cataract surgery.
On corneal disease, on-demand poster data will address persistence of effect for epithelium-on corneal collagen cross-linking in keratoconus.
Glaukos also set an April 10 educational symposium to spotlight Epioxa, described as first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202604060700BIZWIRE_USPR_____20260406_BW850093) on April 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625675022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-06 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625675022","market":"us","top_or_hot":-1,"title":"Glaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Glaukos disclosed multiple clinical study readouts on its glaucoma implants and corneal cross-linking therapy slated for presentation at ASCRS Annual Meeting in Washington on April 10-13, 2026.\n        </li>\n<li>\n          Scheduled talks include follow-up results for third-generation trabecular micro-bypass stents, with outcomes positioned to support durability of pressure-lowering benefit in open-angle glaucoma.\n        </li>\n<li>\n          Additional presentations will cover real-world experience combining micro-bypass stents with Glaukos intracameral travoprost implant, highlighting treatment-effect persistence and use alongside cataract surgery.\n        </li>\n<li>\n          On corneal disease, on-demand poster data will address persistence of effect for epithelium-on corneal collagen cross-linking in keratoconus.\n        </li>\n<li>\n          Glaukos also set an April 10 educational symposium to spotlight Epioxa, described as first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202604060700BIZWIRE_USPR_____20260406_BW850093) on April 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-06 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Glaukos disclosed multiple clinical study readouts on its glaucoma implants and corneal cross-linking therapy slated for presentation at ASCRS Annual Meeting in Washington on April 10-13, 2026.\n        </li>\n<li>\n          Scheduled talks include follow-up results for third-generation trabecular micro-bypass stents, with outcomes positioned to support durability of pressure-lowering benefit in open-angle glaucoma.\n        </li>\n<li>\n          Additional presentations will cover real-world experience combining micro-bypass stents with Glaukos intracameral travoprost implant, highlighting treatment-effect persistence and use alongside cataract surgery.\n        </li>\n<li>\n          On corneal disease, on-demand poster data will address persistence of effect for epithelium-on corneal collagen cross-linking in keratoconus.\n        </li>\n<li>\n          Glaukos also set an April 10 educational symposium to spotlight Epioxa, described as first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202604060700BIZWIRE_USPR_____20260406_BW850093) on April 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065731478.USD","symbol_name":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL95XCps:1","article_id":"2625675022","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625675022","pubTimestamp":1775473231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Glaukos disclosed multiple clinical study readouts on its glaucoma implants and corneal cross-linking therapy slated for presentation at ASCRS Annual Meeting in Washington on April 10-13, 2026.Scheduled talks include follow-up results for third-generation trabecular micro-bypass stents, with outcomes positioned to support durability of pressure-lowering benefit in open-angle glaucoma.Additional presentations will cover real-world experience combining micro-bypass stents with Glaukos intracameral travoprost implant, highlighting treatment-effect persistence and use alongside cataract surgery.On corneal disease, on-demand poster data will address persistence of effect for epithelium-on corneal collagen cross-linking in keratoconus.Glaukos also set an April 10 educational symposium to spotlight Epioxa, described as first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","GKOS":"Glaukos Corp"},"translate_title":"Glaukos在ASCRS会议上公布新型圆锥角膜筛查设备的临床计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":0.9},"content_text":"Glaukos unveils clinical plan for novel keratoconus screening device at ASCRS meeting\n    \n\n\n          Glaukos disclosed multiple clinical study readouts on its glaucoma implants and corneal cross-linking therapy slated for presentation at ASCRS Annual Meeting in Washington on April 10-13, 2026.\n        \n\n          Scheduled talks include follow-up results for third-generation trabecular micro-bypass stents, with outcomes positioned to support durability of pressure-lowering benefit in open-angle glaucoma.\n        \n\n          Additional presentations will cover real-world experience combining micro-bypass stents with Glaukos intracameral travoprost implant, highlighting treatment-effect persistence and use alongside cataract surgery.\n        \n\n          On corneal disease, on-demand poster data will address persistence of effect for epithelium-on corneal collagen cross-linking in keratoconus.\n        \n\n          Glaukos also set an April 10 educational symposium to spotlight Epioxa, described as first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202604060700BIZWIRE_USPR_____20260406_BW850093) on April 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625675022","isCrawlerRequest":true}